Should investors take a shot on this name. Joining us now is Learing Partner, senior managing director, Dr. . Mani Faruar.Uh Dr. . Mani, thanks for joining us. >> A pleasure to join you.>> Uh you got accelerating an $18 price target. So I'm guessing that you don't understand why it's so high, but can you um concede there though that there are a number of of cancer readouts that are due uh later this year and the stock might find some lift here. Oh, it's 100% uh critical cancer story.This is a stock that has ...